Brain-Derived Tau (BD-Tau) Biology and the Resolution of Peripheral Confounding

Total Tau (t-Tau) has long served as a classical fluid biomarker of acute neuroaxonal injury and cortical neurodegeneration. However, while cerebrospinal fluid (CSF) Total Tau demonstrates high diagnostic fidelity, peripheral blood Total Tau (in plasma and serum) shows relatively weak correlation with CSF levels and neurodegenerative staging (r ≈ 0.30–0.50). This clinical and translational discordance arises because peripheral non-brain tissues—including peripheral nerves, salivary glands, kidney, and liver—express peripheral tau isoforms that leak into the systemic circulation, creating substantial background noise that masks subtle central neuronal release.

Brain-Derived Tau (BD-Tau) resolves this fundamental bioanalytical limitation. Developed through recent landmark breakthroughs (Karikari et al., Brain 2023), BD-Tau is quantified using a bespoke antibody pair that targets a specific junctional epitope unique to brain-derived full-length and truncated tau species while completely avoiding peripheral tau fragments. Circulating blood BD-Tau exhibits exceptional correlation with paired CSF Total Tau (r = 0.85–0.92), mirroring cortical neurodegeneration, post-mortem neurofibrillary tangle burden, and cognitive decline without non-cerebral confounding.

Key Translational Strengths of Circulating Simoa BD-Tau

  • Central Nervous System Specificity: Selectively quantifies brain-derived tau in peripheral blood, eliminating non-specific peripheral tissue background that compromises conventional plasma Total Tau assays.
  • High Blood-to-CSF Fidelity: Blood BD-Tau correlates strongly with CSF Total Tau (r > 0.85), making serial blood draws a non-invasive surrogate for CSF-based neurodegeneration tracking.
  • Sub-Picogram Analytical Sensitivity: Quanterix Simoa digital single-molecule counting achieves functional LLOQs down to 0.020 pg/mL, delivering 100% quantifiable readouts across healthy baseline and diseased cohorts.
  • Complementary ATN Staging: Seamlessly integrates as the "N" (Neurodegeneration) structural marker alongside "A" (Aβ42/40) and "T" (Simoa p-Tau217 or Multi-Epitope Tau) to establish complete ATN fluid biomarker profiling.